<DOC>
	<DOCNO>NCT00064350</DOCNO>
	<brief_summary>RATIONALE : Preclinical study indicate sorafenib potent inhibitor Raf kinase vitro vivo , significant dose-dependent , anti-tumor activity four different human tumor type include colon , pancreatic , lung , ovarian . This activity cytostatic nature maintain dose continue . That , tumor growth suspend drug administer return baseline rate agent withdrawn . Therefore , optimal schedule uninterrupted one . To assess activity sorafenib timely manner meaningful interpretation , randomized discontinuation design adopt present trial , conduct population potentially sensitive sorafenib . PURPOSE : This randomized phase II trial study sorafenib see well work compare placebo treat patient refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine percent patient maintain stable disease objective response two month randomization continue sorafenib treatment , compare patient switch placebo . - To determine progression-free survival , overall survival , response rate . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord number prior chemotherapy regimen ( 2 vs 2 ) prior epidermal growth factor receptor inhibitor treatment ( yes v ) . - Induction : All patient receive oral sorafenib twice daily day 1-28 . Treatment continue 2 course absence disease progression unacceptable toxicity . Patients stable disease proceed randomization . Patients respond disease continue receive sorafenib 1 year absence disease progression . - Randomization : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib twice daily 1 year absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo twice daily 1 year absence disease progression unacceptable toxicity . Patients develop disease progression within 1 year randomization cross arm I . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 311 patient accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm advanced nonsmall cell lung cancer ( NSCLC ) Disease must progress least 2 prior chemotherapy regimen NSCLC Patients must measurable nonmeasurable disease Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( 5 time ULN patient liver disease ) Creatinine le 1.5 time ULN calculate creatinine clearance great 50 mL/min More 3 week since prior chemotherapy , radiotherapy , immunotherapy investigational drug use Recovered prior therapy Fertile patient must use effective contraception Age &gt; = 18 ECOG performance status 01 Prior primary metastatic brain meningeal tumor unless clinically radiographically stable therapy least 2 month Active second malignancy Clinically evident congestive heart failure , serious cardiac arrhythmia , symptom coronary heart disease Prior radiotherapy site measurable evaluable disease unless evidence disease progression site Prior exposure ras pathway inhibitor ( e.g. , farnesyl transferase inhibitor ) Concurrent medication know metabolize liver narrow therapeutic index , include follow : Ketoconazole Itraconazole Quinidine Digoxin Cyclosporine Ritonavir Grapefruit product Carbamazepine Phenytoin Phenobarbital Pregnant nursing Clinically serious active infection Medical condition , substance abuse psychological/social situation would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>sorafenib</keyword>
</DOC>